Biovail Corporation

Company aware of submission for generic Wellbutrin

Published in Pharma Law Weekly, December 28th, 2004

Biovail Corporation (BVF) has been advised that GlaxoSmithKline (GSK) has received a Notice of Patent Certification associated with an abbreviated new drug application (ANDA) that has been submitted to the U.S. Food and Drug Administration (FDA) by Abrika Pharmaceuticals LLP of Sunrise, FL, seeking marketing approval for a 150 mg generic formulation of Wellbutrin XL (once-daily bupropion).

On November 17, Biovail announced that it received notification that Anchen Pharmaceuticals, Inc., had filed an abbreviated new drug application (ANDA) for a generic formulation of Wellbutrin XL.

Chih-Ming Chen, chairman and CEO of Anchen, and Alan Cohen, chairman...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry